In various embodiments, the present invention relates generally to implantable stents and, more specifically, to stents that include elastomeric elements for providing enhanced stent expandability and/or mechanical properties.
A variety of medical conditions are treatable by the implantation of tubular devices into natural body lumens or cavities. For example, it is commonplace to implant metallic stents into the coronary arteries of patients with heart disease following balloon angioplasty to minimize the risk that the arteries will undergo restenosis in the future. Generally, the implantable stents are forcibly compacted to a small diameter by a constraining sleeve or other means during delivery. Following delivery to the desired site, the stent constraints are released and the stent opens to contact the luminal surface of the body.
Recent developments in the field of implantable stents include the use of a tubular covering fitted to the stent, either to the outer surface, the luminal surface or to both surfaces of the stent to decrease the risk of restenosis. These covered stents have generally come to be referred to as stent-grafts. The coverings are generally of a polymeric biocompatible material such as polyethylene terephthalate (PET) or polytetrafluoroethylene (PTFE). Other examples of conventional tubular medical implants include woven grafts that are used to span vascular aneurysms, polymeric tubes and catheters that are used to bypass strictures in the ureter and urethra, and stents that are used in the peripheral vasculature, prostate, and esophagus.
Additionally, several approaches have been used to expand the diameter of a stent after delivery. For example, some stents require the use of a separate expansion device to mechanically apply a radially outward force on the stent walls to increase the stent diameter after delivery. Other stents are designed to be self-expanding, without the need for an extra mechanical expansion device. For example, the stents can be made from coiled or patterned nitinol metal alloys that are superelastic, biocompatible, and have shape memory. The stents are initially fashioned in an expanded state. Prior to implantation, the stent is tightly wound or crimped in order to reduce its diameter, Upon heating above a transition temperature, the shape memory alloy coil reverts to its original shape, with a larger diameter. Conventional self-expanding stents, however, may have limited expandability and mechanical properties.
Conventional stents may expand from their contracted states to their expanded states in a relatively arbitrary manner, e.g., at an inconsistent or variable rate and/or force. Physicians may have no control or selection over the expansion rate or force of such stents. Rapid expansion of a stent within a lumen such as a blood vessel may cause trauma to the lumen or to tissue surrounding the lumen, which may be undesirable. For example, smooth muscle areas lining a blood vessel in which a stent is rapidly expanding may tend to resist an abrupt enlargement of the blood vessel. The inability of the blood vessel walls to rapidly acclimate to the rapidly expanding diameter of the vessel may lead to damage to, or aggravate, the vessel wall. Such damage may lead to, or accelerate, re-occlusion or restenosis of the blood vessel. Restenosis of the vessel may require performance of an additional invasive intervention in the treated area within a relatively short period of time.
Consequently, there is a need for self-expanding stents that provide enhanced stent expandability and controlled expansion rates while being deployed in the desired target site.
In various embodiments, the present invention relates to an implantable tubular medical device for placement within a lumen or cavity of a patient. The device may be formed from a metallic material, such as stainless steel, or one or more polymer strands. In one implementation, the device includes a tubular shape that has multiple open areas and elements that span at least some of the open areas. The elements impart a force that urges proximal and distal portions of the open areas towards each other to thereby provide enhanced expandability and mechanical properties when compared with conventional self-expanding devices. Additionally, the current invention provides self-expanding devices with various controllable expansion forces and/or rates during self-expansion, thereby allowing the physician to select a device with a desirable expansion force and/or rate based on the properties of the target site.
Accordingly, in one aspect, the invention pertains to a medical implant. In various embodiments, the medical implant includes a tubular structure having a proximal end, a distal end, and a sidewall extending between the proximal and distal ends; the sidewall includes multiple open areas. In some embodiments, each open area includes one or more surfaces collectively defining a continuous outer boundary of the open area, a proximal boundary portion defined by the first portion of the surface(s), and a distal boundary portion defined by the second portion of the surface(s); the distal boundary portion is closer than the proximal boundary portion to the distal end of the tubular structure. In various embodiments, the medical implant further includes an element spanning one or more open areas between the proximal and distal boundary portions of the open area(s). In one implementation, when the tubular structure is in a reduced diameter configuration, a distance between the proximal and distal boundary portions is a first distance, and when the tubular structure is in an expanded diameter configuration, a distance between the proximal and distal boundary portions is a second distance; the first distance is greater than said second distance.
In another aspect, the invention relates to a method of manufacturing a medical implant as described herein.
In another aspect, the present invention relates to a method of treating a patient by implanting a medical implant as described herein into a blood vessel or other bodily lumen or cavity of the patient.
In another aspect, the present invention relates to a kit that includes a medical implant as described herein along with a suitable delivery device.
In the drawings, like reference characters generally refer to the same parts throughout the different views. Also, the drawings are not necessarily to scale, with an emphasis instead generally being placed upon illustrating the principles of the invention. In the following description, various embodiments of the present invention are described with reference to the following drawings, in which:
The present invention provides for self-expanding medical implants that have expansion characteristics and mechanical properties that render them suitable for a broad range of applications involving placement within bodily lumens or cavities. As used herein, “device,” “implant,” and “stent” are used synonymously to mean any scaffold, endoprosthesis or other tubular structures that may be implanted into the human body. Also as used herein, “self-expanding” is intended to include devices that are crimped to a reduced configuration for delivery into a bodily lumen or cavity, and thereafter tend to expand to a larger suitable configuration once released from the delivery configuration, either without the aid of any additional expansion devices or with the partial aid of balloon-assisted or similarly-assisted expansion. When compared with conventional self-expanding medical implants, the implants of the present invention recover to a higher percentage of their manufactured diameter after being crimped and held in a small diameter for delivery into a bodily lumen. Moreover, when compared with conventional self-expanding implants and particularly polymeric implants, the implants of the present invention are characterized by much improved strength and other desired mechanical properties.
Examples of stent structures and related technology suitable for use with the present invention are described in U.S. Ser. No. 13/370,025, which is incorporated herein by reference for all purposes. In one embodiment shown in
Referring to
The strands 110, 120 may be made from biostable polymeric or metallic materials. Alternatively, they may be made from one or more biodegradable polymers or metals that are preferably absorbed within about two years of placement within a patient, and more preferably within about one year of placement within a patient. In some embodiments, the strands are fully absorbed within about six or fewer months of placement within a patient. The first and second strand sets 110, 120 may be made from the same or different biodegradable polymer. Non-limiting examples of biodegradable polymers that are useful in the strands of the present invention include poly lactic acid (PLA), poly glycolic acid (PGA), poly trimethylene carbonate (PTMC), poly caprolactone (PCL), poly dioxanone (PDO), and copolymers thereof. Preferred polymers are poly(lactic acid co-glycolic acid) (PLGA) having a weight percentage of up to about 24% lactic acid, or greater than about 79% lactic acid (preferably PLGA 88:12), with the former being stronger but degrading in the body faster. The composition of PLGA polymers within these ranges may be optimized to meet the mechanical property and degradation requirements of the specific application for which the implant is used. The term “biodegradable” is used herein synonymously with “bioabsorbable,” “bioerodible,” “resorbable,” and “bioresorbable” to describe a material or structure that degrades in the human body by any suitable mechanism.
To facilitate the low-profile aspects of the present invention (e.g. during the delivery of the implants into small diameter bodily lumens or cavities), the strands used in the implant 100 preferably have a diameter in the range of from about 75 microns to about 500 microns, and are more preferably less than about 150 microns in diameter. The use of small diameter strands results in an implant with minimal wall thickness and the preferred ability to collapse (i.e., to be crimped) within low diameter catheter delivery systems. Where multiple strands are used, they may be of substantially equal diameters within this range, or first strand set 110 may be of a different general diameter than second strand set 120. In either event, the diameters of strands are chosen so as to render the implant 100 preferably deliverable from a 10 French delivery catheter (i.e., 3.3 mm diameter) or smaller, and more preferably from a 7 French delivery catheter. (i.e., 2.3 mm diameter) or smaller. The ability to place the implant of the present invention into small diameter delivery catheters allows for its implantation into small diameter bodily lumens and cavities, such as those found in the vascular, biliary, uro-genital, iliac, and tracheal-bronchial anatomy. Exemplary vascular applications include coronary as well as peripheral vascular placement, such as in the superficial femoral artery (SFA). It should be appreciated, however, that the implants of the present invention are equally applicable to implantation into larger bodily lumens, such as those found in the gastrointestinal tract.
Referring to
Referring to
For example, the element 310 may be formed when the implant is in its unstressed, as-manufactured state (case I), 10% diameter reduced configuration (case II), or 50% diameter reduced configuration (case III). Upon placement of the stent into a reduced diameter configuration suitable for delivery into the body, the element 310 in case I is under the largest stress, whereas the element 310 in case III is under the smallest stress. When the implant is deployed at the desired target site, the element 310 in case I may create the largest contraction force, which then results in the highest expansion force and/or rate. By contrast, the element 310 in case III may generate the smallest contraction force, which may then result in the lowest expansion rate. Therefore, by adjusting the configuration (e.g., fully expanded, slightly crimped, or fully crimped) of the implant during the element formation, various degrees of stress on the strengthening means may be formed when the stents are in the low-profile state (e.g., having a reduced diameter configuration) during delivery. Once the stents are released from the low-profile state, the expansion force and/or rate of the implant upon being released from the delivery configuration may be well controlled and tuned (e.g., the stents that include a large stress strengthening means may expand with a higher expansion rate compared with those stents that include a small stress strengthening means). Accordingly, the current invention allows the physician to select an appropriate implant with a desirable expansion force and/or rate based on the tissue properties of the target site.
The element 310 may be made from an elastomeric polymer that, due to its elastic nature when compressed or elongated, applies a force to implant 100 that acts in favor of radial expansion and axial contraction, thus enhancing radial strength. The polymer of the connecting elements 310 is preferably biodegradable. Alternatively, the connecting elements 310 may be made from a shape memory material (e.g., nitinol) or a material that otherwise contracts upon heating to body temperature.
Examples of polymer materials used for the element 310 include suitable thermoplastic or thermoset elastomeric materials that yield the elongation, mechanical strength and low permanent deformation properties when combined with the implant strand(s). The inventors have found examples of suitable polymers to include certain random copolymers such as poly(lactic acid-co-caprolactone) (PLCL), poly(glycolide-co-caprolactone) (PGCL), and poly(lactic acid-co-dioxanone) (PLDO), certain homopolymers such as poly trimethylene carbonate (PTMC), and copolymers and terpolymers thereof. Such polymers are optionally crosslinked with a crosslinker that is bi- or multi-functional, polymeric, or small molecule to yield a thermoset polymer having a glass transition temperature (Tg) that is preferably lower than body temperature (37° C.), more preferably lower than room temperature (25° C.), and most preferably lower than about 5° C. The thermoset elastomers provide a high elongation to break with low permanent deformation under cyclic mechanical testing.
In one preferred embodiment, the polymer material used for the element 310 is a biodegradable thermoset elastomer synthesized from a four arm PGCL polymer having a weight ratio of approximately 50:50 GA:CL that is crosslinked with hexamethylene diisocyanate (HDI) to give a polyester with urethane crosslinks. Without wishing to be bound by theory, the inventors believe that the combination of the elastic segment (polyester portion) and the interactions (such as hydrogen bonding, allophanate or biuret formation) between the urethane segments of such polymers, in addition to a certain crosslinking density, yields preferred properties such as a high degree of elastic recovery under cyclic mechanical strain and high overall elasticity.
In other preferred embodiments, the element 310 comprises PLCL having about 45 to 75 weight percent lactic acid (e.g., a weight ratio of approximately 50:50 PL:CL). In yet another preferred embodiment, the element 310 comprises a PLCL 50:50 crosslinked with hexamethylene diisocyanate and the braided implant comprises a PLGA 79:21.
Methods for manufacturing exemplary tubular implants useful in the present invention are described in U.S. Ser. No. 13/370,025. Additionally, various techniques may be used to form the element 310 on the implant. Referring to
Referring to
Referring to
In another embodiment of the present invention, the implant is a non-woven, self-expanding structure, such as a unitary polymeric framework. As shown in
Certain embodiments of the present invention were described above. It is, however, expressly noted that the present invention is not limited to those embodiments, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.
Reference throughout this specification to “one example,” “an example,” “one embodiment,” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment,” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, routines, steps, or characteristics may be combined in any suitable manner in one or more examples of the technology. The terms “substantially” and “approximately” mean ±10% and, in some embodiments, within ±5%. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed technology.
This application claims priority to and the benefit of, and incorporates herein by reference in its entirety, U.S. Provisional Patent Application No. 61/728,873, which was filed on Nov. 21, 2012.
Number | Date | Country | |
---|---|---|---|
61728873 | Nov 2012 | US |